Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
| Status: | Recruiting |
|---|---|
| Conditions: | Skin Cancer, Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/24/2019 |
| Start Date: | August 10, 2017 |
| End Date: | August 28, 2024 |
| Contact: | Amgen Call Center |
| Email: | medinfo@amgen.com |
| Phone: | 866-572-6436 |
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC®
(Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic
Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in
Treated Patients
(Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic
Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in
Treated Patients
Inclusion Criteria:
- Patient has provided written informed consent
- Patient is an adult (≥ 18 years of age at the time of informed consent) with a
diagnosis of melanoma
- Patient enrolled within 1 month of receiving the first dose of IMLYGIC for the
treatment of melanoma
Exclusion Criteria:
- Patient has a prior history of being a subject in an interventional clinical trial for
IMLYGIC
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials